It has been demonstrated that the expression of HO-1, a target gene of NRF2, is involved in the protection against photofrin-PDT toxicity and that HO-1 inhibitors potentiate the anti-tumor effect of PDT [37]. The gene discussed is NFE2L2; the disease is neoplasm.